| http://dbpedia.org/ontology/abstract
|
Asset-centricity is an approach to investi … Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development. The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely held belief that it has become too expensive. It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital. A typical asset-centric startup company would have a single asset, or sometimes two, with a team of experts, including drug developers, shared across a back-end structure and across a variety of portfolio life sciences companies. These team members would coalesce for specific, focused drug-discovery projects The bulk of funding would support the development of the primary asset, with the rest supporting a secondary asset and infrastructure.ting a secondary asset and infrastructure.
|
| http://dbpedia.org/ontology/wikiPageID
|
49314159
|
| http://dbpedia.org/ontology/wikiPageLength
|
4656
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
990241445
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/AbbVie +
, http://dbpedia.org/resource/Research_&_development +
, http://dbpedia.org/resource/Pharmaceutical +
, http://dbpedia.org/resource/Eli_Lilly +
, http://dbpedia.org/resource/Drug_discovery +
, http://dbpedia.org/resource/Investing +
, http://dbpedia.org/resource/Molecule +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Janssen_Pharmaceuticals +
, http://dbpedia.org/resource/Drug +
, http://dbpedia.org/resource/Index_Ventures +
, http://dbpedia.org/resource/Atlas_Venture +
, http://dbpedia.org/resource/Startup_company +
, http://dbpedia.org/resource/Category:Finance_theories +
, http://dbpedia.org/resource/Life_sciences +
, http://dbpedia.org/resource/Venture_capital +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Finance_theories +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Approach +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Asset-Centricity?oldid=990241445&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Asset-Centricity +
|
| owl:sameAs |
http://yago-knowledge.org/resource/Asset-Centricity +
, https://global.dbpedia.org/id/2MjmM +
, http://www.wikidata.org/entity/Q25112031 +
, http://dbpedia.org/resource/Asset-Centricity +
|
| rdf:type |
http://dbpedia.org/ontology/ProgrammingLanguage +
|
| rdfs:comment |
Asset-centricity is an approach to investi … Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development. The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely held belief that it has become too expensive. It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital. of improving returns on invested capital.
|
| rdfs:label |
Asset-Centricity
|
